MedPage Today (1/14, George) reported “hospitalized patients with COVID-19 and no prior history of dementia had elevated levels of brain injury biomarkers,” according to an observational study published in Alzheimer’s & Dementia. Investigators examined “data from 251 hospitalized COVID-19 patients without a history of dementia, assessing seven serum markers of neurodegeneration: t-tau, p-tau181, GFAP, NfL, UCHL1, amyloid beta 40, and amyloid beta 42,” and then compared the biomarker levels “with 161 controls without COVID-19, including 54 people with no cognitive impairment, 54 people with mild cognitive impairment, and 53 people with Alzheimer’s disease dementia.” (SOURCE: APA Headlines)